Recent Updates
Recently added Catalysts
ENLV Positive Sentiment

Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion

Key Takeaway: Enlivex Ltd. has reported a net asset value (NAV) of $66.16 per ordinary share as of July 18, 2026. The company holds approximately $1.1 billion in RAIN tokens, reflecting its dual strategy of developing longevity therapeutics while engaging in digital asset markets. The update highlights both the company's strong asset position and the inherent risks associated with cryptocurrency volatility and regulatory uncertainties.
Price reaction · baseline $4.68 (2026-07-17 close) · hit pre-market · clean, no other ENLV news in the window
day 0 close · peak
-0.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Enlivex's NAV per ordinary share is $66.16, indicating strong asset value.
  • The company holds a substantial amount of RAIN tokens valued at approximately $1.1 billion.
  • Enlivex is advancing its clinical-stage immunotherapy, Allocetra™, targeting aging-related conditions.

CONCERNS & RISKS

  • The company faces risks related to the volatility of cryptocurrency markets.
  • There are uncertainties regarding regulatory conditions affecting digital assets.
  • Potential competition in the longevity therapeutics and digital asset sectors could impact performance.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+34%
120-day peak, hindsight
Typical move
9.4%
average across 8 past catalysts
Lead asset
Allocetra
Phase 2 · Primary Knee Osteoarthritis

Full Press Release Details

As of July 18, 2026, net asset value (NAV1) per share was $66.16
As of July 18, 2026, Enlivex held 79,550,593,122 RAIN tokens with a total value of approximately $1.1 billion2.
Nes-Ziona, Israel, July 20, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today provided an update on its RAIN token holdings. As of July 18, 2026, the net asset value (NAV1) per ordinary share was $66.16, and the Company held 79,550,593,122 RAIN tokens with a total value of approximately $1.1 billion2.
The updated unaudited mark-to-market treasury metrics are publicly available on the Company's website athttps://enlivex.com/dashboard/. Detailed information about the RAIN token’s listing on various exchanges, daily trading volume and other parameters can be found onhttps://coinmarketcap.com/currencies/rain/.
About EnlivexEnlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem.
Forward-looking statementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would," "could," "intends," "estimates," "suggests," "target," "has the potential to," "goal," and other words of similar meaning, including statements relating to the anticipated benefits of the Company's digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company's ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company's plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs.
Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Company's digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company's operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company's ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law.

Enlivex contactShachar ShlosbergerCFOEnlivex Ltd.shachar@enlivex.com

1Net asset value per share: the total treasury valuation divided by the total number of outstanding ordinary shares2Valuation calculated using the closing price of the RAIN token as quoted onhttps://coinmarketcap.com/currencies/rain/

Frequently Asked Questions

What is the NAV per ordinary share for Enlivex?

The NAV per ordinary share for Enlivex is $66.16 as of July 18, 2026.

How much are Enlivex's RAIN token holdings valued at?

Enlivex's RAIN token holdings are valued at approximately $1.1 billion.

What is Allocetra™ developed by Enlivex?

Allocetra™ is an advanced clinical-stage immunotherapy targeting inflammatory conditions related to aging.

What risks does Enlivex face regarding its digital assets?

Enlivex faces risks from cryptocurrency market volatility and regulatory uncertainties.

Last updated: Jul 20, 2026